In vivo evolution of carbapenem resistance in hypervirulent Klebsiella pneumoniae in a patient undergoing long-term treatment
J Antimicrob Chemother
.
2022 Feb 2;77(2):531-533.
doi: 10.1093/jac/dkab380.
Authors
Na Tang
1
2
,
Jinshu Hu
3
,
Yingying Zhao
1
,
Yuqin Song
1
,
Chao Wang
1
,
Gang Zhang
1
,
Dawei Wei
1
2
,
Hailing Fang
1
,
Chao Li
1
,
Rufu Jia
3
,
Jie Feng
1
Affiliations
1
State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
2
College of Life Science, University of Chinese Academy of Sciences, Beijing, China.
3
Cangzhou Central Hospital, Cangzhou, China.
PMID:
34726753
DOI:
10.1093/jac/dkab380
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Carbapenems / pharmacology
Carbapenems / therapeutic use
Humans
Klebsiella Infections* / drug therapy
Klebsiella pneumoniae* / genetics
Substances
Carbapenems